tiprankstipranks
Trending News
More News >
Checkpoint Therapeutics (CKPT)
:CKPT
US Market
CKPT
Checkpoint Therapeutics
RESEARCH TOOLSreports
Advertisement

Checkpoint Therapeutics (CKPT) Price & Analysis

Compare
Followers

CKPT Stock Chart & Stats


Checkpoint Therapeutics News

CKPT FAQ

What was Checkpoint Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Checkpoint Therapeutics’s market cap?
Currently, no data Available
When is Checkpoint Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Checkpoint Therapeutics’s earnings last quarter?
Currently, no data Available
Is Checkpoint Therapeutics overvalued?
According to Wall Street analysts Checkpoint Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
    Does Checkpoint Therapeutics pay dividends?
    Checkpoint Therapeutics does not currently pay dividends.
    What is Checkpoint Therapeutics’s EPS estimate?
    Checkpoint Therapeutics’s EPS estimate for its next earnings report is not yet available.
    How many shares outstanding does Checkpoint Therapeutics have?
    Currently, no data Available
    What happened to Checkpoint Therapeutics’s price movement after its last earnings report?
    Currently, no data Available
    Which hedge fund is a major shareholder of Checkpoint Therapeutics?
    Currently, no hedge funds are holding shares in CKPT

    Company Description

    Checkpoint Therapeutics

    Checkpoint Therapeutics, Inc. (CKPT) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of immuno-oncology and targeted therapy treatments for patients with solid tumor cancers. The company focuses on developing a robust pipeline of novel combination therapies aimed at treating various cancer indications. Checkpoint Therapeutics' lead product candidates include cosibelimab, an anti-PD-L1 antibody, and CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor.

    Checkpoint Therapeutics (CKPT) Earnings & Revenues

    Currently, no data available
    Please return soon. This page is being updated.
    Similar Stocks
    Company
    Price & Change
    Follow
    Eton Pharmaceuticals
    Phathom Pharmaceuticals
    Amylyx Pharmaceuticals Inc
    Zenas BioPharma, Inc.
    Upstream Bio, Inc.

    Ownership Overview

    4.52%95.48%
    Insiders
    4.52%
    Mutual Funds
    ― Other Institutional Investors
    95.48% Public Companies and
    Individual Investors

    Options Prices

    Currently, No data available
    ---
    Popular Stocks
    What am I Missing?
    Make informed decisions based on Top Analysts' activity
    Know what industry insiders are buying
    Get actionable alerts from top Wall Street Analysts
    Find out before anyone else which stock is going to shoot up
    Get powerful stock screeners & detailed portfolio analysis